M. Fernández Castro

ORCID: 0000-0003-4081-2751
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Salivary Gland Disorders and Functions
  • Systemic Sclerosis and Related Diseases
  • Salivary Gland Tumors Diagnosis and Treatment
  • Systemic Lupus Erythematosus Research
  • Oral Health Pathology and Treatment
  • Rheumatoid Arthritis Research and Therapies
  • Monoclonal and Polyclonal Antibodies Research
  • Celiac Disease Research and Management
  • Healthcare Systems and Technology
  • Galectins and Cancer Biology
  • Urticaria and Related Conditions
  • Growth Hormone and Insulin-like Growth Factors
  • Atherosclerosis and Cardiovascular Diseases
  • T-cell and B-cell Immunology
  • Hepatitis C virus research
  • Ocular Surface and Contact Lens
  • Oral microbiology and periodontitis research
  • Otitis Media and Relapsing Polychondritis
  • Chronic Lymphocytic Leukemia Research
  • Antioxidant Activity and Oxidative Stress
  • Hepatitis B Virus Studies
  • Hip disorders and treatments
  • Immunotherapy and Immune Responses
  • Shoulder Injury and Treatment
  • Immunodeficiency and Autoimmune Disorders

Hospital Universitario Puerta de Hierro Majadahonda
2011-2025

Hospital Universitario Infanta Sofía
2015-2021

University Hospital Complex Of Vigo
2016

Excel Life Sciences (India)
2015

Academy of Management
2015

Association for Nutrition
2015

Manifattura Italiana del Brembo (Italy)
2015

Jacobson Holman (United States)
2015

Universidad Autónoma de Madrid
2007-2012

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2012

Maureen D. Mayes Lara Bossini‐Castillo Olga Y. Gorlova José-Ezequiel Martín Xiaodong Zhou and 95 more Wei V. Chen Shervin Assassi Binwu Ying Filemon K. Tan Frank C. Arnett John D. Reveille Sandra G. Guerra María Teruel F. David Carmona Peter K. Gregersen Annette T. Lee Elena López‐Isac Eguzkine Ochoa Patrícia Carreira Carmen Pilar Simeón‐Aznar I. Castellví Miguel Á. González‐Gay Alexandra Zhernakova Leonid Padyukov Marta E. Alarcón‐Riquelme Cisca Wijmenga Matthew A. Brown Lorenzo Beretta Gabriela Riemekasten Torsten Witte Nicolas Hunzelmann Alexander Kreuter Jörg H. W. Distler Alexandre E. Voskuyl Annemie J. Schuerwegh Roger Hesselstrand Annica Nordin Paolo Airò Claudio Lunardi Paul G. Shiels Jacob M. van Laar Ariane L. Herrick Jane Worthington Christopher P. Denton Fredrick M. Wigley Laura K. Hummers John Varga Monique Hinchcliff Murray Baron Marie Hudson Janet Pope Daniel E. Furst Dinesh Khanna Kristin Phillips Elena Schiopu Barbara Segal Jerry A. Molitor Richard M. Silver Virginia Steen Robert W. Simms Robert Lafyatis Barri J. Fessler Tracy Frech Firas Alkassab Peter Docherty Elżbieta Kamińska Nader Khalidi Henry Niall Jones Janet Markland David Robinson Jasper Broen Timothy R. D. J. Radstake Carmen Fonseca Bobby P. C. Koeleman Javier Martı́n Norberto Ortego‐Centeno Raquel Ríos José Luis Callejas‐Rubio Nuria Navarrete Navarrete Rosa García Portales María Teresa Camps Antonio Fernández‐Nebro María Francisca González‐Escribano Julio Sánchez-Román Francisco José García Hernández María Jesús Castillo M. Á. Aguirre Inmaculada Gómez-Gracia Benjamín Fernández‐Gutiérrez Luis Rodríguez‐Rodríguez Esther Vicente José Luís Andreu M. Fernández Castro Paloma García de la Peña Francisco Javier López-Longo L. Martínez V Fonollosa Gerard Espinosa Carlos Tolosa A. Pros

10.1016/j.ajhg.2013.12.002 article EN publisher-specific-oa The American Journal of Human Genetics 2014-01-01

Objective: This study aimed to investigate the effectiveness and safety of single repeated courses rituximab in patients with refractory lupus. Methods: LESIMAB is a multicenter, retrospective, longitudinal lupus who have not responded standard therapy been treated rituximab. Response rates at six months follow-up were defined as efficacy outcomes. Complete response was SELENA-SLEDAI score ≤ two Flare Index zero. Partial reduction ≥four points no new or worsening symptoms. Adverse events...

10.1177/0961203312446627 article EN Lupus 2012-07-11

Systemic sclerosis (SSc) is a fibrotic autoimmune disease in which the genetic component plays an important role. One of strongest SSc association signals outside human leukocyte antigen (HLA) region corresponds to interferon (IFN) regulatory factor 5 (IRF5), major regulator type I IFN pathway. In this study we aimed evaluate whether three different haplotypic blocks within locus, have been shown alter protein function influencing systemic lupus erythematosus (SLE) susceptibility, are...

10.1371/journal.pone.0054419 article EN cc-by PLoS ONE 2013-01-23

Shoulder pain is a common complaint, frequently caused by subacromial impingement syndrome (SIS). There are number of physical examination (PE) manoeuvres that explore the space. MRI provides an accurate anatomic image space, being current gold standard in diagnosis SIS. The aim this study to evaluate accuracy PE SIS and/or subacromial-subdeltoid bursitis (SSB) confirmed MRI.Consecutive outpatients with episode shoulder were prospectively included study. They examined rheumatologist and,...

10.1093/rheumatology/ken101 article EN Lara D. Veeken 2008-01-29

A single-nucleotide polymorphism (SNP) at the IL12RB2 locus showed a suggestive association signal in previously published genome-wide study (GWAS) systemic sclerosis (SSc). Aiming to reveal possible implication of gene SSc, we conducted follow-up this different Caucasian cohorts. We analyzed 10 GWAS-genotyped SNPs region (2309 SSc patients and 5161 controls). then selected three (rs3790567, rs3790566 rs924080) based on their significance level GWAS, for an independent European cohort...

10.1093/hmg/ddr522 article EN Human Molecular Genetics 2011-11-10

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple organ involvement and pronounced racial ethnic heterogeneity. The aims of the present work were (1) to describe cumulative clinical characteristics those patients included in Spanish Rheumatology Society SLE Registry (RELESSER), focusing on differences between who fulfilled 1997 ACR-SLE criteria versus with less than 4 (hereafter designated as incomplete (iSLE)) (2) compare patient documented other...

10.1097/md.0000000000000267 article EN cc-by-nc Medicine 2015-01-01

Abstract Objective The aim of the present study was to describe demographic, clinical and immunological characteristics patients with late-onset (≥50 years) SLE vs early-onset (<50 years). Methods We performed a cross-sectional retrospective 3619 from RELESSER database (National Register Patients Systemic Lupus Erythematosus Spanish Society Rheumatology). Results A total 565 (15.6%) were classified as 3054 (84.4%) SLE. male-to-female ratio 5:1. Mean (s.d.) age at diagnosis in group...

10.1093/rheumatology/keaa477 article EN Lara D. Veeken 2020-07-16

The aim of this study is to analyze if the results Oral Health Impact Profile-14 questionnaire (OHIP-14) in patients with primary Sjögren's syndrome (pSS) are correlated salivary flow and level xerostomia.This observational cross-sectional was conducted 61 (60 women, one man, mean age 57.64 [13.52]) diagnosed pSS according American-European Criteria (2002). After recording demographic, medical dental data (decayed-missing-filled teeth index [DMFT]), unstimulated (UWS) stimulated (SWS) flows...

10.1111/jop.13348 article EN cc-by-nc-nd Journal of Oral Pathology and Medicine 2022-08-23

Objectives. To identify patterns (clusters) of damage manifestations within a large cohort SLE patients and evaluate the potential association these clusters with higher risk mortality. Methods. This is multicentre, descriptive, cross-sectional study 3656 from Spanish Society Rheumatology Lupus Registry. Organ was ascertained using Systemic International Collaborating Clinics Damage Index. Using cluster analysis, groups similar were identified. Then, overall compared as well subgroup every...

10.1093/rheumatology/kew049 article EN Lara D. Veeken 2016-03-27

To quantify the mortality risk in a large, well-characterized cohort of Sjögren's disease (SjD) patients and to identify independent predictors this population. We included 314 diagnosed with SjD according 2002 American-European Consensus Group criteria from prospective, multicenter SjögrenSER-PROS cohort. Detailed data on systemic manifestations, serological markers, activity, was collected after 9 years follow up. The primary outcome overall mortality, secondary analyses aimed using Cox...

10.3899/jrheum.2024-1033 article EN The Journal of Rheumatology 2025-01-15

Objective To compare the prevalence of main comorbidities in 2 large cohorts patients with primary Sjögren's syndrome (SS) and systemic lupus erythematosus (SLE), a focus on cardiovascular (CV) diseases. Methods This was cross‐sectional multicenter study where more relevant compared. Patients under followup from SJOGRENSER (Spanish Rheumatology Society Registry Primary SS) RELESSER SLE), who fulfilled 2002 American–European Consensus Group 1997 American College classification criteria,...

10.1002/acr.23015 article EN Arthritis Care & Research 2016-08-26

Background: Candidiasis is the most frequent mycotic infection of oral cavity.The aim this study was to investigate presence clinical candidiasis and Candida albicans yeast in a population diagnosed primary Sjögren's syndrome (pSS) possible factors associated with infection.Material Methods: An observational cross-sectional conducted 61 pSS patients (60 women, 1 man, mean age 57.64±13.52)where patient based information (demographic medical, tobacco alcohol consumption history), intraoral...

10.4317/medoral.23719 article EN Medicina oral, patología oral y cirugía bucal 2020-01-01

Primary Sjögren's syndrome (pSS) is an autoimmune disease, characterized by lymphocytic infiltration of exocrine glands and other organs, resulting in dry eye, mouth extraglandular systemic findings.To explore the association severe or very eye with extraocular involvement patients diagnosed primary syndrome.SJOGRENSER registry a multicenter cross-sectional study pSS patients. For construction our main variable, severe/very we used those variables that represented degree 3-4 severity...

10.1007/s00296-018-4013-5 article EN cc-by Rheumatology International 2018-03-20
Coming Soon ...